In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
The price of Blueprint Medicines Corp (NASDAQ: BPMC) closed at $92.26 in the last session, down -0.03% from day before closing price of $92.29. In other words, the price has decreased by -$0.03 from its previous closing price. On the day, 0.56 million shares were traded. BPMC stock price reached its highest trading level at $93.74 during the session, while it also had its lowest trading level at $90.43.
Ratios:
We take a closer look at BPMC’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 3.66 and its Current Ratio is at 3.76. In the meantime, Its Debt-to-Equity ratio is 5.93 whereas as Long-Term Debt/Eq ratio is at 5.30.
On August 21, 2023, Needham reiterated its Buy rating and also lowered its target price recommendation from $65 to $66.
Wells Fargo Upgraded its Equal Weight to Overweight on July 31, 2023, whereas the target price for the stock was revised from $55 to $82.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Mar 28 ’24 when Landsittel Michael sold 5,000 shares for $95.00 per share. The transaction valued at 475,000 led to the insider holds 47,286 shares of the business.
Albers Jeffrey W. sold 25,073 shares of BPMC for $2,188,264 on Mar 20 ’24. The Director now owns 176,050 shares after completing the transaction at $87.28 per share. On Mar 15 ’24, another insider, Landsittel Michael, who serves as the CHIEF FINANCIAL OFFICER of the company, sold 13,734 shares for $87.78 each. As a result, the insider received 1,205,606 and left with 47,286 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BPMC now has a Market Capitalization of 5649292288 and an Enterprise Value of 5712772608. For the stock, the TTM Price-to-Sale (P/S) ratio is 22.65 while its Price-to-Book (P/B) ratio in mrq is 43.19. Its current Enterprise Value per Revenue stands at 22.908 whereas that against EBITDA is -12.037.
Stock Price History:
Over the past 52 weeks, BPMC has reached a high of $101.00, while it has fallen to a 52-week low of $43.89. The 50-Day Moving Average of the stock is 2.88%, while the 200-Day Moving Average is calculated to be 32.07%.
Shares Statistics:
According to the various share statistics, BPMC traded on average about 790.23K shares per day over the past 3-months and 623860 shares per day over the past 10 days. A total of 61.15M shares are outstanding, with a floating share count of 59.80M. Insiders hold about 2.33% of the company’s shares, while institutions hold 106.32% stake in the company. Shares short for BPMC as of 1711584000 were 4372399 with a Short Ratio of 5.53, compared to 1709164800 on 5136028. Therefore, it implies a Short% of Shares Outstanding of 4372399 and a Short% of Float of 9.6.
Earnings Estimates
The stock of Blueprint Medicines Corp (BPMC) is currently being evaluated by 15.0 analysts who are actively contributing to its market rating.On average, analysts expect EPS of -$1.66 for the current quarter, with a high estimate of -$1.46 and a low estimate of -$1.8, while EPS last year was -$2.15. The consensus estimate for the next quarter is -$1.48, with high estimates of -$1.22 and low estimates of -$1.63.
Analysts are recommending an EPS of between -$4.37 and -$6.28 for the fiscal current year, implying an average EPS of -$5.55. EPS for the following year is -$2.78, with 15.0 analysts recommending between -$0.27 and -$6.46.
Revenue Estimates
According to 15 analysts, the current quarter’s revenue is expected to be $80.88M. It ranges from a high estimate of $86.7M to a low estimate of $72M. As of the current estimate, Blueprint Medicines Corp’s year-ago sales were $63.29MFor the next quarter, 15 analysts are estimating revenue of $92.7M. There is a high estimate of $103M for the next quarter, whereas the lowest estimate is $87M.
A total of 16 analysts have provided revenue estimates for BPMC’s current fiscal year. The highest revenue estimate was $449M, while the lowest revenue estimate was $372M, resulting in an average revenue estimate of $393M. In the same quarter a year ago, actual revenue was $249.38MBased on 16 analysts’ estimates, the company’s revenue will be $596.03M in the next fiscal year. The high estimate is $738.9M and the low estimate is $481.18M.
